Compare EYE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYE | SRPT |
|---|---|---|
| Founded | 1990 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2017 | 2000 |
| Metric | EYE | SRPT |
|---|---|---|
| Price | $28.17 | $22.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 28 |
| Target Price | ★ $31.22 | $25.24 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 03-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | $1,987,488,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $75.86 | ★ N/A |
| Revenue Growth | 9.00 | ★ 15.58 |
| 52 Week Low | $10.45 | $10.42 |
| 52 Week High | $30.02 | $72.05 |
| Indicator | EYE | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 69.44 |
| Support Level | $25.33 | $20.61 |
| Resistance Level | $29.37 | $22.73 |
| Average True Range (ATR) | 1.13 | 1.06 |
| MACD | 0.10 | 0.75 |
| Stochastic Oscillator | 77.32 | 84.04 |
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.